CDR-Life Inc. has announced CDR-609 as its next clinical candidate. Built on the company’s proprietary M-gager platform, CDR-609 is a novel T-cell engager targeting LGR5, a surface antigen widely expressed on common solid tumors, including colorectal, gastric, liver and pancreatic cancers.